MaaT Pharma Publishes its Half Year 2025 Results and Provides a Business Update Positive results from Phase 3 trial for…
Categorie
2025
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program…
July 28, 2025
MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux Lyon, France, July 24, 2025 – 6:00pm CET –…
July 24, 2025
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
July 7, 2025
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe MaaT Pharma and…
July 2, 2025
MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting Lyon, France, June 24, 2025 – 8:00pm…
June 24, 2025
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 Marketing Authorization application of Xervyteg® (MaaT013) in…
June 19, 2025
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed…
June 13, 2025
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in…
June 2, 2025
MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress…
May 14, 2025
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.